Methylphenidate HCL for the treatment of ADHD in children and adolescents

References

• American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.
   Google Scholar
• Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56(3):345–365.
   PubMed Web of Science ®Google Scholar
• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
   PubMed Web of Science ®Google Scholar
• Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022.
   PubMed Web of Science ®Google Scholar
• Polaha J, Dalton WT 3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106–1112.
   PubMed Web of Science ®Google Scholar
• Ritalin hydrochloride® (methylphenidate hydrochrloride USP tablets) CII Prescribing Information. [cited 2016 Feb 7] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010187s080,018029s049,021284s027lbl.pdf
   Google Scholar
• Comments on the Reported Statistics on Psychotropic Substances. [cited 2016 Feb 7] Available from: http://www.incb.org/documents/Psychotropics/technical-publications/2012/en/5_Part_II_comments.pdf
   Google Scholar
• Controlled Substances Security Manual. [cited 2015 Feb 8] Available from: http://www.deadiversion.usdoj.gov/pubs/manuals/sec/app_law.htm
   Google Scholar
• Top 25 Psychiatric Medication Prescriptions for 2013. [[cited 2016 Feb 8]. Available from: http://psychcentral.com/lib/top-25-psychiatric-medication-prescriptions-for-2013/
   Google Scholar
• Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(Suppl 1):S31–S43.
   Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353–364.
   PubMed Web of Science ®Google Scholar
• Martin A. Pediatric psychopharmacology: principles and practice. Oxford; New York: Oxford University Press; 2003.
   Google Scholar
• Hechtman L, Abikoff H. Multimodal treatment plus stimulants vs. stimulant treatment in ADHD children: results from a two-year comparative treatment study. Presented at the 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 1995 Oct 18–26; New Orleans, LA.
   Google Scholar
• Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs. 2003;5(12):787–794.
   PubMedGoogle Scholar
• Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40(2):188–196.
   PubMed Web of Science ®Google Scholar
• Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404.
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Stein MA, Cooper KM. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. J Child Adolesc Psychopharmacol. 2010;20(3):187–196.
   PubMed Web of Science ®Google Scholar
• Gerwe M, Stollhoff K, Mossakowski J, et al. Tolerability and effects of OROS(R) MPH (Concerta (R)) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial. Atten Defic Hyperact Disord. 2009;1(2):175–186.
   PubMedGoogle Scholar
• Manos M, Frazier TW, Landgraf JM, et al. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin. 2009;25(12):3001–3010.
   PubMed Web of Science ®Google Scholar
• Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample. Aust N Z J Psychiatry. 2007;41(12):998–1004.
   PubMed Web of Science ®Google Scholar
• Haertling F, Mueller B, Bilke-Hentsch O. Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin (R) LA) in school children under daily practice conditions. Atten Defic Hyperact Disord. 2015;7(2):157–164.
   PubMedGoogle Scholar
• Dopfner M, Breuer D, Walter D, et al. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes. Eur Child Adolesc Psychiatry. 2011;20(Suppl 2):S277–S288.
   Google Scholar
• Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118(3):e704–e710.
   Google Scholar
• Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50–e62.
   Google Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6):E105.
   PubMed Web of Science ®Google Scholar
• Raman SR, Marshall SW, Gaynes BN, et al. An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom. Psychiatr Serv. 2015;66(6):617–624.
   PubMed Web of Science ®Google Scholar
• Kordon A, Stollhoff K, Niederkirchner K, et al. Exploring the impact of once-daily OROS(R) methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgrad Med. 2011;123(5):27–38.
   PubMed Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION. CONCERTA® (methylphenidate HCl) Extended-Release Tablets CII. [cited 2016 Feb 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021121s035lbl.pdf
   Google Scholar
• Armstrong RB, Damaraju CV, Ascher S, et al. Time course of treatment effect of OROS(R) methylphenidate in children with ADHD. J Atten Disord. 2012;16(8):697–705.
   PubMed Web of Science ®Google Scholar
• Ritalin LA. Prescribing Information (methylphenidate hydrochloride extended-release capsules). [cited 2016 May 8]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_la.pdf
   Google Scholar
• Silva R, Muniz R, Pestreich LK, et al. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol. 2005;15(4):637–654.
   PubMed Web of Science ®Google Scholar
• Once Daily Metadate CD® (methylphenidate HCl, USP) Extended-Release Capsules CII Prescribing Information. [cited 2016 Feb 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021259s029lbl.pdf
   Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004;113(3 Pt 1):e206–e216.
   Google Scholar
• McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9(3):476–485.
   PubMedGoogle Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION DAYTRANA® (methylphenidate transdermal system). [cited 2016 Feb 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021514s023lbl.pdf
   Google Scholar
• Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004;310(2):469–476.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Boellner SW, Lopez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):700–708.
   PubMed Web of Science ®Google Scholar
• Wigal SB, Childress AC, Belden HW, et al. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013;23(1):3–10.
   PubMed Web of Science ®Google Scholar
• Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010;122(5):35–41.
   PubMed Web of Science ®Google Scholar
• Childress AC, Sallee FR, Berry SA. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad Med. 2011;123(5):80–88.
   PubMed Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION QUILLIVANT XR® (methylphenidate hydrochloride) for extended-release oral suspension, CII. [cited 2016 Feb 8] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202100s004lbl.pdf
   Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION APTENSIO XR™ (methylphenidate hydrochloride extended-release) Capsules, for oral use. CII. [cited 2016 Feb 8] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205831s000lbl.pdf.
   Google Scholar
• Wigal SB, Greenhill LL, Nordbrock E, et al. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(10):562–569.
   PubMed Web of Science ®Google Scholar
• Focalin® (dexmethylphenidate hydrochloride) Capsules CII for oral use Prescribing Information. [cited 2016 Feb 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021278s018,021802s028lbl.pdf
   Google Scholar
• Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs. 2008;22(8):693–704.
   PubMed Web of Science ®Google Scholar
• Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(2):199–208.
   PubMed Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION QUILLICHEW ERTM (methylphenidate hydrochloride) extended-release chewable tablets, for oral use, CII. [cited 2016 Feb 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207960s000lbl.pdf
   Google Scholar
• Tengler M, Stark JG, Childress A, et al. Pharmacokinetics of a novel methylphenidate extended-release orally disintegrating tablet formulation. Poster presented at the American Professional Society of ADHD and Related Disorders Annual Meeting; 2016 Jan 15–17; Washington, DC.
   Google Scholar
• Childress A, Kollins SH, Cutler AJ, et al. A new formulation of methylphenidate phase 3 study of the efficacy and tolerability of an extended-release orally disintegrating tablet in children 6-12 years of age with ADHD. Poster presented at the American Academy of Child and Adolescent Psychiatry 62nd Annual Meeting; 2015 Oct 26–31; San Antonio, TX.
   Google Scholar
• Childress A, Stark JG, Sikes C, et al. The pharmacokinetic properties of a novel extended-release oral disintegrating tablet formulation of methylphenidate in children and adolescents with ADHD. Poster presented at the American Academy of Child and Adolescent Psychiatry 62nd Annual Meeting; 2015 Oct 26–31; San Antonio, TX.
   Google Scholar
• Childress A, Desousa NJ, Incledon B, et al. The single dose pharmacokinetics of HLD200: a modified release methylphenidate (MPH) formulation in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Poster presented at the American Professional Society of ADHD and Related Disorders Annual Meeting; 2015 Jan 16–18; Washington, DC.
   Google Scholar
• McDonnell M, Wigal S, Childress A, et al. A phase III endpoint evaluation of HLD200 in children with attention deficit hyperactivity disorder: safety results. Poster presented at the American Professional Society of ADHD and Related Disorders Annual Meeting; 2016 Jan 15–17; Washington, DC
   Google Scholar
• Highland Therapeutics Announces Positive Top-Line Data from a Phase III Trial. [cited 2016 Feb 8]. Available from: http://highlandtherapeutics.com/pdf/Highland_Announces_Phase_III_Data_FINAL.pdf
   Google Scholar
• PRC-063 in an ADULT Workplace Environment. [cited 2016 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02225639?term=prc063&rank=3
   Google Scholar
• Storebo OJ, Krogh HB, Ramstad E, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.
   PubMed Web of Science ®Google Scholar
• Storebo OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885.
   Google Scholar
• Winterstein AG. Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies. Curr Psychiatry Rep. 2013;15(8):379.
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Kvist AP, Leckman JF, et al. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol. 2014;24(6):302–310.
   PubMed Web of Science ®Google Scholar
• Palumbo D, Spencer T, Lynch J, et al. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004;14(2):185–194.
   PubMed Web of Science ®Google Scholar
• Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005;90(8):801–806.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179–185.
   PubMed Web of Science ®Google Scholar
• Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604–609.
   PubMed Web of Science ®Google Scholar
• Childress AC, Sallee FR. Emotional lability in patients with attention-deficit/hyperactivity disorder: impact of pharmacotherapy. CNS Drugs. 2015;29(8):683–693.
   PubMed Web of Science ®Google Scholar
• Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985;142(5):547–552.
   PubMed Web of Science ®Google Scholar
• Rosler M, Retz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry. 2010;11(5):709–718.
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–165.
   PubMed Web of Science ®Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–179.
   PubMed Web of Science ®Google Scholar
• Hanwella R, Senanayake M, De Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176.
   PubMed Web of Science ®Google Scholar
• Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581–588.
   PubMed Web of Science ®Google Scholar
• Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36(2):141–155.
   PubMed Web of Science ®Google Scholar
• Johnston BA, Coghill D, Matthews K, et al. Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study. J Psychopharmacol. 2015;29(1):24–30.
   PubMed Web of Science ®Google Scholar
• Ogrim G, Kropotov J, Brunner JF, et al. Predicting the clinical outcome of stimulant medication in pediatric attention-deficit/hyperactivity disorder: data from quantitative electroencephalography, event-related potentials, and a go/no-go test. Neuropsychiatr Dis Treat. 2014;10:231–242.
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237–248.
   PubMed Web of Science ®Google Scholar
• Silberg JL, Gillespie N, Moore AA, et al. Shared genetic and environmental influences on early temperament and preschool psychiatric disorders in Hispanic twins. Twin Res Hum Genet. 2015;18(2):171–178.
   PubMed Web of Science ®Google Scholar
• Stein MA, Waldman I, Newcorn J, et al. Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(5):238–244.
   PubMed Web of Science ®Google Scholar
• Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30(7):1374–1382.
   PubMed Web of Science ®Google Scholar
• McGough J, McCracken J, Swanson J, et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1314–1322.
   PubMed Web of Science ®Google Scholar
• Froehlich TE, Epstein JN, Nick TG, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(11):1129–39e2.
   Google Scholar
• Kambeitz J, Romanos M, Ettinger U. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics J. 2014;14(1):77–84.
   PubMed Web of Science ®Google Scholar
• McGough JJ, McCracken JT, Loo SK, et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1155–1164.
   PubMed Web of Science ®Google Scholar
• Johnson KA, Barry E, Lambert D, et al. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. J Child Adolesc Psychopharmacol. 2013;23(10):655–664.
   PubMed Web of Science ®Google Scholar
• Gazer-Snitovsky M, Brand-Gothelf A, Dubnov-Raz G, et al. High familial correlation in methylphenidate response and side effect profile. J Atten Disord. 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2012;44(1):78–84.
   Web of Science ®Google Scholar
• Jones G, Dejesus-Rosario N, Kao C, et al. Exploratory dose-escalation study of NFC-1 in ADHD adolescents with glutamatergic gene network variants. Poster presented at the American Academy of Child and Adolescent Psychiatry 62nd Annual Meeting; 2016 Oct 26–31; San Antonio, TX.
   Google Scholar